TrialRMD open2025

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension.

Atul Deodhar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.